SCHEMBL3335966

SCHEMBL3335966

CC(=O)Nc1nc(OC(C)C)c2cc(-c3ccc(F)cc3)ccc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.40
ADORA2A P29274 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ADORA1 P30542 1/20 0.39
MAP4K4 O95819 1/20 0.38
PIK3CG P48736 2/20 0.38
NAMPT P43490 3/20 0.38
MAPK1 P28482 2/20 0.38
RAB9A P51151 1/20 0.38
PDPK1 O15530 1/20 0.38
DYRK1A Q13627 1/20 0.38
NPR1 P16066 1/20 0.37
PIK3CA P42336 1/20 0.37
LRRK2 Q5S007 1/20 0.36
DHODH Q02127 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338081 0.90 BRAF (0.46) ADORA3CYP1A2CYP2C19ADORA1RAB9A
SCHEMBL3337967 0.89 DHODH (0.40) ADORA3ADORA2ACYP1A2CYP2C9CYP2C19
SCHEMBL3340764 0.87 CYP1A2 (0.43) ADORA3ADORA2ACYP1A2ADORA1MAP4K4
SCHEMBL3336257 0.84 PIK3CG (0.49) ADORA3CYP1A2PIK3CGMAPK1DYRK1A
SCHEMBL3335301 0.84 PIK3CA (0.41) ADORA3ADORA2AADORA1MAP4K4PIK3CG
SCHEMBL3334908 0.84 ADORA3 (0.40) ADORA3ADORA2AADORA1MAP4K4PIK3CG
SCHEMBL3335675 0.84 MAPT (0.41) ADORA3ADORA2AADORA1MAP4K4PIK3CG
SCHEMBL3335706 0.82 NAMPT (0.42) ADORA3ADORA2ACYP1A2CYP2C19ADORA1
SCHEMBL3336253 0.81 PTGS1 (0.42) ADORA3ADORA2AADORA1MAP4K4NAMPT
SCHEMBL3341530 0.81 PIK3CA (0.44) ADORA3ADORA2AADORA1MAP4K4PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ADORA3 483/4885ADORA2A 1968/4885CYP1A2 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.